First in Human Safety Study of FX-345 in Adults With Sensorineural Hearing Loss
A Phase 1b, Prospective, Randomized, Single-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety of FX-345 Administered as a Single Intratympanic Injection in Adults With Acquired Adult-Onset Sensorineural Hearing Loss
Sponsor: Frequency Therapeutics
Terminated
Business reasons
Other Hearing Loss, Sensorineural trials with similar outcome
A PHASE1 clinical study on Hearing Loss, Sensorineural, this trial is terminated or withdrawn. The trial is conducted by Frequency Therapeutics and has accumulated 5 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
May 2023 — Jul 2024 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Mar 2023 — May 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2023 — Mar 2023 [monthly]
Recruiting PHASE1
First recorded
Dec 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Frequency Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .